Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14

28 novembre 2018

09:00
The Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Los Angeles Biomedical Research Institute, and University of Washington School of Medicine today announced the launch of the first...

08:33
Ajinomoto Bio-Pharma Services (« Aji Bio-Pharma »), fournisseur leader de services de développement et de fabrication biopharmaceutique sous contrat, a présenté des données lors du World ADC Summit de San Diego ce mois-ci, en décrivant sa technologie...

08:32
Biomarck Pharmaceuticals, Ltd today announced that it has completed enrollment in the Phase 2 study in NSCLC. This study compares standard of care, (pemetrexed/carboplatin. SOC) to SOC plus BIO-11006 in 60 patients with stage 4, NSCLC.   Currently...

08:30
Positive results from clinical trials are headlining the current market for pancreatic cancer treatments in the active biotech industry. Pancreatic cancer is one of the deadliest cancers in the world, but only $90 million is spent annually on...

08:03
Natera, Inc. , a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for the company's kidney transplant rejection assay, representing a key reimbursement milestone in preparation for the commercialization of its...

07:31
EyeMax Mono implantation results in an improved mean visual acuity of 18 ETDRS letters and 57% increase in mean reading speed   LEH Pharma Ltd, a leading provider of innovative technologies for macular disorders, today announces new data published...

07:00
By stirring crosstalk among skin cells that form the roots of hair, researchers report they have regrown hair strands on damaged skin. The findings better explain why hair does not normally grow on wounded skin, and may help in the search for better...

06:12
Cancer immunotherapy ? the treatment approach that utilizes and enhances the power of the immune system - looks promising. Alternative or complementary approaches are also being investigated to enhance the efficacy of the present generation of cancer...

06:00
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective...

05:00
Cryoablation?the destruction of cancer cells through freezing?shows early indications of effectiveness in treating women with low-risk breast cancers, according to research being presented today at the annual meeting of the Radiological Society of...

05:00
Researchers using functional MRI (fMRI) have found differences in the brains of men and women who are addicted to online gaming, according to a new study presented today at the annual meeting of the Radiological Society of North America (RSNA)....

03:00
Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive results in the toxicology studies. The drug candidate T20K has now shown to be safe for people to...

03:00
GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has developed a solution to integrate IHC, FISH, NGS and Karyotyping in order to provide therapy and clinical trial recommendations.  This innovative work...

01:17
Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:...


27 novembre 2018

16:01
Protagonist Therapeutics, Inc. today announced that the Company plans to begin clinical development of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the treatment of inflammatory bowel disease (IBD). In preclinical...

14:59
Generex Biotechnology Corporation has signed a clinical trial agreement (CTA) with the NSABP Foundation, Inc. (NSABP), to manage a Phase II clinical trial of Pembrolizumab (Keytruda®) in combination with the AE37 Peptide Vaccine in Patients with...

13:00
WATCH THE VIDEO: https://youtu.be/RxtNlABLbqc Infertility is a major clinical concern, affecting 15% of all reproductive-age couples. Pollution, smoking and trends toward a Western-style diet (generally characterized by processed and refined foods,...

12:41
A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world. The IND.234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses...

12:31
A newfound genetic regulatory mechanism may both shape the ability of the immune system to fight viral infections, and be central to autoimmune diseases that occur when immune cells attack bodily tissues instead. A new study led by researchers at...

10:43
Besting more than 50 research study applications, medical researcher Dr. Aurora Serralde Zúñiga's entry on the study of omega-3 fatty acids in hospital patients requiring parenteral nutrition with intestinal failure-associated complications won the...

10:08
Researchers from MedStar Washington Hospital Center and MedStar Health Research Institute will begin an Investigational Device Exemption (IDE) trial on full-thickness burn wounds using Kerecis Omega3 Burn. The Kerecis...

10:00
HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with nonalcoholic steatohepatitis (NASH).  ...

09:00
QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, today announced the expansion of its U.S.-based Phase I clinical trial capabilities to support the growing needs of its...

08:30
Constant Pharmaceuticals today announced that it plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with four EB focused charities - DEBRA (Austria),...

08:15
Menarini Silicon Biosystems announced today that new hem-oncology research utilizing the company's DEPArraytm single-cell isolation technology will be featured at the upcoming scientific meeting of the American Society of Hematology. In two separate...

08:15
Equashield (equashield.com), a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, today announced it will demonstrate the launch version of its CSTD-enabled Equashield® Pro Robot at the upcoming ASHP Midyear Meeting....

08:08
Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS). The symposium will be held...

08:00
(PBT.U: CSE, PTGEF: OTC Markets) ? Further to its news release of November 21, 2018, Portage Biotech Inc. ("Portage" or the "Company") is very pleased to announce that it has published and posted its shareholder meeting materials which provide...

08:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into an agreement with Roche to collaborate on the development of a new HER2 low companion diagnostic test. Under the terms of the agreement, Roche will...

08:00
Autonomous Healthcare, Inc. has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant for $746,668 to commercialize a clinical decision support fluid management system for intensive care unit (ICU)...

07:55
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-8236, a novel, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor which has demonstrated potency...

07:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the VENTANA pan-TRK (EPR17341) Assay, the first automated in vitro diagnostic (IVD) immunohistochemistry (IHC) assay to detect tropomyosin receptor kinase (TRK) proteins in...

07:00
Ionis Pharmaceuticals, Inc. , the leader in antisense therapeutics, today announced that data from the IONIS-TMPRSS6-LRx Phase 1 study, TEGSEDItm (inotersen) and other Ionis research and development programs will be presented at the 60th American...

05:12
GB Sciences, Inc. is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid...

05:00
A minimally invasive procedure in which pulses of energy from a probe are applied directly to nerve roots near the spine is safe and effective in people with acute lower back pain that has not responded to conservative treatment, according to a study...

04:18
WATCH THE VIDEO: https://youtu.be/RxtNlABLbqc Infertility is a major clinical concern, affecting 15% of all reproductive-age couples. Pollution, smoking and trends toward a Western-style diet (generally characterized by processed and refined foods,...

02:00
Ces tests contribuent à prévenir l'ulcère gastrique et le cancer gastrique  L'infection par Helicobacter pylori est un grave problème de santé publique, touchant 60 % de la population mondiale, 90 % des ulcères gastriques et 80 % des cancers...


26 novembre 2018

20:43
The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene...

17:26
Eyenovia, Inc. , a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III...

16:00
Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced the presentation of two posters on DB102 (Enzastaurin) at the American Society of Hematology conference that takes place from Saturday,...

15:45
Foresee Pharmaceuticals Co., Ltd. (6576.TWO), a annoncé aujourd'hui que tous les patients ont finalisé l'essai multicentrique, multinational, de phase 3, du FP-001/LMIS (suspension injectable de leuprolide mésylate) de 25 mg, une formulation...

11:28
CannaLean, an Israeli company committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from dyslipidemia, has completed in vivo studies...

10:00
CHICAGO, Nov. 26, 2018 /PRNewswire-PRWeb/ -- RADLogics, the pioneer in Machine-Learning driven medical imaging analysis solutions, showcases results from a first-of-its-kind clinical study evaluating the effect of an integrated detection and report...

09:00
World Institute of Kimchi, which discovers and promotes kimchi's scientific excellence announces that the results of an animal test showed that lactic...

09:00
Alcyone Lifesciences, Inc., a leader in breakthrough technologies to treat complex oncolytic and neurological conditions through the company's proprietary advanced precision delivery platform, announced that the first patient was treated with...

09:00
DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L). The first-in-human Phase 1 study is evaluating the safety and...

08:30
Ampio Pharmaceuticals, Inc. today updates the regulatory and peer-review publication status of Ampion. Regulatory update:Statisticians representing Ampio and the FDA met recently to discuss the clinical pathway of...

08:30
Foresee Pharmaceuticals Co., Ltd. (6576.TWO) today announced that all patients had completed participation in its Phase 3, multinational, multicenter trial of FP-001/LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg, a three-month, ready-to-use...

08:00
Seegene Inc. (096530.KQ), a leading developer of multiplex PCR assays, announced that multi-site clinical trials for measuring clinical performance on screening the drug resistance of Enterobacteriaceae with the Allplextm Entero-DR assay have been...

08:00
MicuRx Pharmaceuticals, Inc., today announced that the first patient has been enrolled in a Phase 2 clinical trial of contezolid acefosamil for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive...

1 2 3 4 5 6 7 8 9 10 11 12 13 14